Our objectives were: (1) to determine the efficacy, safety, and tolerability of sildenafil citrate (Viagra 1 ) administered to men with broad-spectrum erectile dysfunction (ED) in southern Latin America; and (2) to correlate Rigiscan 1 measurements assessing ED etiology with the investigator's assessment. A total of 141 men with broad-spectrum ED (mean age 57) were enrolled in a randomized, 12-week, double-blind, placebo-controlled, flexible-dose escalation study of sildenafil. After the 12-week treatment period, the mean score for the primary efficacy variables had risen significantly: for the sildenafil group, 66.2% from baseline for question 3 of the International Index of Erectile Function and 77.6% for question 4, vs 15.1% and 21.2% for the placebo group, respectively (P < 0.0001). Rigiscan 1 data confirmed investigator assessments of etiology. Headache and flushing, usually mild and transient, were the most common adverse events. Sildenafil was an effective, well-tolerated treatment for men in southern Latin America with broad-spectrum ED.
Introduction
Erectile dysfunction (ED) is defined as the persistent inability to achieve or maintain an erection sufficient to permit satisfactory sexual intercourse. 1 It has been estimated to affect up to 30 million men in the USA. 2, 3 ED may result from psychological, neurologic, hormonal, vascular, or cavernosal impairment or from a combination of these factors. 4, 5 The disorder is age-associated, 2 -5 with estimated prevalence rates of roughly 39% among men 40-y-old and 67% among those 70-y-old.
Normal penile erection depends on the relaxation of smooth muscles in the corpora cavernosa. In response to sexual stimuli, cavernous nerves and endothelial cells release nitric oxide (NO), which stimulates the formation of cyclic guanosine monophosphate (cGMP) by guanylate cyclase. 4 Cyclic GMP in turn activates a specific protein kinase, which phosphorylates certain proteins, resulting in the opening of potassium channels and hyperpolarization of the muscle cell membrane, sequestration of intracellular calcium by the endoplasmic reticulum, and blocking of calcium influx by the inhibition of calcium channels. 4 The consequence is a drop in cytosolic calcium concentrations and relaxation of the smooth muscle. During the return to the flaccid state, cGMP is hydrolyzed to GMP by phosphodiesterase type 5 (PDE5). 4 Other phosphodiesterases are also found in the corpus cavernosum, but they do not appear to have an important role in the erection process. Sildenafil citrate (Viagra 1 , Pfizer Inc, New York, NY, USA) is a selective inhibitor of cGMP-specific PDE5. 6 -8 By selectively inhibiting cGMP catabolism in cavernosal smooth muscle cells, sildenafil enables the natural erection response to sexual stimulation, but does not cause erections in the absence of such stimulation.
In a number of randomized, placebo-controlled, double-blind, and open-label studies, sildenafil has been shown to be an effective oral treatment for male ED and to have an adequate safety profile. 9 -14 Whether the results of these initial double-blind and open-label randomized trials can be extrapolated to a population-based sample of men with ED in Latin America remains to be determined. Therefore, the objectives of the present study were to determine the efficacy, safety, and tolerability of sildenafil over a 12-week period, taken as required, prior to anticipated sexual activity in male outpatients with objectively determined broadspectrum etiology. The patients were all from southern Latin America (Argentina, Chile, Peru, and Uruguay). This was also the first study to objectively classify ED etiology through Rigiscan 1 (Timm Medical Technologies, Eden Prairie, MN) measurements and to correlate it with the investigator's clinical assessment.
Methods
This was a double-blind, randomized, placebocontrolled, multicenter, parallel-group, flexible-dose escalation study. Each man had to be in a stable relationship with a female partner of at least 6 months' duration. The cause and etiology of the ED were determined from the medical history, physical examination, and other diagnostic procedures, including a Rigiscan test (nocturnal penile tumescence [NPT] testing). The penile tumescence and rigidity measure was performed at the base and=or tip of the penis at the prescreening evaluation. This monitoring of nocturnal erections was performed at home for two nights, with a monitoring period of at least 5 h per night, in order to distinguish between psychogenic and organic ED, and to enable the investigators to perform a subanalysis according to the established etiology. The results of this NPT testing were expressed as the mean average rigidity reached by the patients during the monitoring period.
Men were excluded if they had penile anatomical defects, a primary diagnosis of another sexual disorder (for example, premature ejaculation), spinal cord injury, any major psychiatric disorder not well controlled with treatment, poorly controlled diabetes mellitus, a history of alcohol or substance abuse, major hematological, renal, or hepatic abnormalities, hypotension (sitting blood pressure < 90=50 mm Hg) or malignant hypertension, a recent (occurring within the previous 6 months) stroke or myocardial infarction, or if they were receiving nitrates.
The institutional review board at each center approved the protocol, and all the men gave written informed consent to participate.
To confirm the diagnosis of male ED after the preliminary evaluation and following a 4-week runin period with no treatment, during which baseline data on sexual function were collected, patients entered a 12-week double-blind treatment period. The men were instructed to take a dose of the study drug approximately 1 h before planned sexual activity but no more than once daily. Patients were only allowed to drink up to two units of alcohol prior to sexual activity, as alcohol may impair the ability to have erections, and thus potentially cause the treatment to be less effective. A total of six study visits were conducted to provide assessments of efficacy, safety, and tolerability. Following randomization, patients returned to the clinic for followup visits after 2, 4, 8, and 12 weeks of treatment.
Other concomitant medications, which could have an effect on erectile function, remained constant during the study, unless changes were required for patient safety.
Patients who experienced no adverse events (AEs) with the 50-mg dose of sildenafil (or corresponding placebo), but whose ED was insufficiently improved at this dose, could increase their dose to 100 mg at the subsequent visit. Patients who responded well at a particular dose were not allowed to receive higher doses. Patients who were receiving the 50-or 100-mg dose were allowed to decrease the dose to the next lowest level only if they were experiencing intolerable or severe AEs. Any dose adjustments between regularly scheduled visits were done for safety purposes only. Sildenafil was provided as 25-, 50-, and 100-mg tablets in bottles (14 tablets=bottle).
At weeks 0 (baseline) and 12, each participant completed the International Index of Erectile Function (IIEF), a 15-question validated, multidimensional, self-administered questionnaire used for the clinical assessment of ED and treatment outcomes in clinical studies. 15, 16 The global efficacy assessment question (GEAQ) ('Did treatment improve your erections?') was asked at week 12. Event logs (patient diaries) were completed after each attempt at sexual intercourse and reviewed at each study visit.
The primary efficacy measures in this study were the responses to questions 3 (Q3, ability to achieve an erection) and 4 (Q4, ability to maintain an erection) of the IIEF. IIEF responses were rated on a scale of 1 ('almost never=never') to 5 ('almost always=always'). A score of 0 indicated no attempt at sexual intercourse. The secondary efficacy measures in the study were the responses to the GEAQ and the responses on the event log, including the proportion of successful attempts at intercourse.
In addition, the responses to the IIEF were used to evaluate the effect of sildenafil or placebo on five domains of male sexual erectile function (questions 1 -5, and question 15 of the IIEF; possible total score 1 -30), orgasmic function (questions 9 and 10 of the IIEF; possible total score 0 -10), sexual desire (questions 11 and 12 of the IIEF, possible total score 2 -10), intercourse satisfaction (questions 6, 7, and 8 of the IIEF; possible total score 0 -15), and overall satisfaction (questions 13 and 14 of the IIEF; possible total score 2 -10). The domain scores were computed by adding the scores for the individual questions in each domain.
All observed or volunteered AEs, regardless of treatment group or suspected causal relationship to study drug, were recorded by the investigators.
Statistical analysis
The treatment groups were checked for similarity with respect to demographic and event log variables using descriptive statistics. Continuous variables are presented as mean AE standard deviation or median and total ranges. Discrete variables are given as frequencies and percentages. Univariate statistical testing was performed with the likelihood ratio chisquare test with Yates' correction or Fisher's exact test, as appropriate, for discrete variables, and with two-sample t-tests or Mann -Whitney tests as appropriate for continuous variables. The primary time point for the primary efficacy and secondary efficacy analyses was the end of double-blind therapy (week 12).
Each of the two questions defining the primary efficacy measure (Q3 and Q4) were analyzed separately, using analysis of covariance (ANCOVA) methods specified below. Significant results at the 5% level in both the analyses were required to demonstrate efficacy over placebo. An ANCOVA method was fitted for each question, which included main-effect terms for investigational center and treatment effect (as ordered categorical variables), with baseline score, patient age, smoking, and duration and cause of ED as covariates.
The answers to the GEAQ (yes or no) were analyzed using logistic regression analysis, accounting for the same covariates as those listed for the ANCOVA models. The proportion of successful attempts at intercourse derived from the event log data were analyzed using a general linear model. All significance tests comprised all subjects receiving active medication, regardless of the dose actually taken, into a single group, and all patients receiving placebo, regardless of the number of tablets actually taken, into another single group. All reported probability values are 2-tailed, and P-values < 0.05 were accepted as statistically significant. All statistical analyses were performed using SAS System for Windows version 6.12 software (Cary, NC).
Results

Demographics
A total of 156 patients underwent the prescreening; 146 were randomized after giving written informed consent. Three screened patients were excluded from the study because they did not take the study medication and were lost to follow-up. (They did not enter in the active treatment phase.) The remaining 143 patients entered the active treatment phase of the study (93 patients from Argentina, 24 from Peru, 15 from Chile, and 11 from Uruguay). Seventy-two patients were assigned to receive active treatment with sildenafil and 71 to the placebo group. Two patients from the placebo group were lost to follow-up after visit two. The Study Project Team assumed they took one dose of study drug. Therefore, they were included in the final safety datasets and excluded from the efficacy analysis. In summary, 141 patients were considered for the efficacy analysis and 143 patients were included in the safety analysis.
Baseline characteristics
Baseline characteristics of the patients are summarized in Table 1 . No significant differences were observed between both treatment groups in terms of age, race, mean body weight (kg), average height (cm), time elapsed since the first diagnosis of ED, and smoking status.
The more frequent and=or relevant concomitant illnesses present in each patient group at the time of enrolment are listed in Table 2 . In the overall population sample, 25 patients had diabetes mellitus (17.5%). No significant differences were observed between the sildenafil and the placebo groups in the prevalence of any concomitant illness (for example, 31.9% had hypertension in the sildenafil vs 43.6% in the placebo groups, respectively). The most frequent=relevant used drugs are summarized in Table 3 (some patients received more than one concomitant drug). No significant difference was observed in the use of concomitant medications between treatment groups. Data on baseline erectile dysfunction Figure 1 shows the observed severity (%) of ED according to the erectile function domain of the IIEF 16 at the baseline visit. Fifty-one percent of the study population sample presented moderate ED in the baseline assessment. The remaining patients were distributed as follows: 7.8% had mild ED, 24.3% had mild to moderate ED, and 17.1% had severe ED.
The investigator judged etiology of the ED to be psychogenic in 44.3% of the patients, organic in 39.3%, and mixed in 16.4%. A baseline Rigiscan measurement was also performed on each patient to evaluate the causality of the ED. The Rigiscan measurements confirmed the investigator's assessment of organicity. The average rigidity (mean percentage AE s.d.) according to etiology was 85.4 AE 9.8% (psychogenic), 54.4 AE 26.9% (organic), and 73.9 AE 18.7% (mixed).
Duration of therapy=number of doses taken
The median number of doses taken by the patients was 33 (range 1 -80) in the sildenafil group and 31 (range 1 -83) in the placebo group. The average number of doses taken per month were 15.2 in the sildenafil group and 14.4 in the placebo group.
After 12 weeks of treatment, the proportions of men taking 25-mg, 50-mg, and 100-mg sildenafil were 5.5% (four men), 34.7% (25 men), and 50% (36 men), respectively. For the group taking placebo, the corresponding proportions were 0% (0 men), 11.6% (8 men), and 82.6% (57 men).
Efficacy
The primary efficacy measures in this study were the responses to Q3 and Q4 of the IIEF at baseline and at the end of the 12 weeks in an intent-to-treat analysis. The mean scores for Q3 and Q4 were significantly higher after treatment for the sildenafil group than for the placebo group (P < 0.0001) (Table 4, Figure 2 ). The percentage increase from baseline was 66.2% for Q3 and 77.6% for Q4 for the men taking sildenafil, whereas it was 15.1% and 21.2% for those taking placebo, respectively.
The analysis of the primary efficacy endpoint using only patients who completed the 12-week treatment period yield a similar result. After a 12-week treatment period, the mean score for Q3 was Sildenafil citrate in the treatment of ED in Latin America E Becher et al 3.9 AE 0.2 (s.e.) for the patients taking sildenafil vs 2.8 AE 0.2 (s.e.) for those taking placebo (P < 0.0001). The mean score for Q4 was 3.8 AE 0.2 (s.e.) for the patients taking sildenafil vs 2.4 AE 0.2 (s.e.) for those taking placebo (P < 0.0001). The secondary efficacy measures in the study included the responses to the GEAQ, the separate responses to the five domains of male sexual function of the IIEF (erectile function, orgasmic function, sexual desire, intercourse satisfaction, overall satisfaction), and the proportion of successful attempts at intercourse. The mean score for the erectile function domain was significantly higher for the men taking sildenafil (20.5 AE 0.6) than for those taking placebo (15.9 AE 0.7; P < 0.0001) ( Figure 3A) . The mean scores for the orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction were also significantly higher in the sildenafil group ( Figure 3B -E) . These results were consistent across all questions constituting the five domains. The separate statistical analyses of each question yielded similar results, showing that the sildenafil group achieved significantly better scores than the placebo group throughout the entire questionnaire (Table 5 ).
After 12 weeks of treatment, improved erections were reported by 77.3% (CI 95%, 65.6 -85.8) of the patients taking sildenafil as compared with 33.8% (CI 95%, 23.4 -46.1) of those taking placebo (P ¼ 0.0001) (Figure 4 ). Nearly 63% of all attempts at sexual intercourse by the men receiving sildenafil were successful as compared with 26.5% for those receiving placebo (P ¼ 0.0051) ( Figure 5) .
The analysis of the responses to Q3 and Q4 of the IIEF according to baseline rigidity measurements reached results similar to those of the entire patient cohort. The mean scores for Q3 and Q4 achieved by sildenafil were higher than those for placebo for patients with Rigiscan rigidity measurements 70% (Q3 sildenafil, 3.6 vs placebo, 2.8; Q4 sildenafil, 3.2 vs placebo, 2.4) or > 70% (Q3 sildenafil, 4.0 vs placebo, 2.7; Q4 sildenafil, 3.9 vs placebo, 2.4), as well as for those patients with Rigiscan rigidity measurements 50% (Q3 sildenafil, 3.6 vs placebo, 2.8; Q4 sildenafil, 3.3 vs placebo, 2.2) or > 50% (Q3 sildenafil, 3.9 vs placebo, 2.7; Q4 sildenafil, 3.7 vs placebo, 2.5).
Safety
All 143 patients enrolled in this study were considered for safety analysis. Discontinuation rates were low. During active treatment, seven of the 72 patients receiving sildenafil (9.7%) and six of the 71 patients taking placebo (8.5%) discontinued treatment. None of the discontinuations were related to the study drug in the opinion of the investigator. Two men (2.8%) in the sildenafil group stopped taking the drug due to nontreatment-related AEs (diabetic coma and motor vehicle accident, respectively), and one patient (1.4%) in the placebo group died.
Forty-three patients (59.7%) in the sildenafil group reported AEs compared with 21 patients (29.6%) in the placebo group (P ¼ 0.079, not significant) (Table 6 ). Two patients in the sildenafil group and one in the placebo group experienced Sildenafil citrate in the treatment of ED in Latin America E Becher et al serious AEs. None of the serious AEs were considered to be related to the study drug in the investigator's judgment. The most frequently reported AEs are summarized in Table 6 . Patients enrolled in the sildenafil treatment arm experienced significantly more flushing (22.2%) and headache (23.6%) than those receiving placebo (flushing 4.2%, P ¼ 0.003; headache 8.4%, P ¼ 0.05). None of these events were serious, and they were frequently mild and transient in nature. One patient in the placebo group experienced a myocardial infarction that ended in the patient's death. None of the men taking sildenafil experienced a myocardial infarction or an acute ischemic syndrome. No significant differences were observed between the sildenafil and placebo groups in the rates of the remaining AEs (Table 6 ). The summary of AEs according to their severity and corresponding treatment group showed that almost 89% of the AEs in the sildenafil group were Figure 4 Global efficacy assessment question.
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E Becher et al mild, 7.7% moderate, and only 3.5% severe. None of the severe AEs were considered related to study drug according to the investigator's judgment. In the placebo group, 63.4% of the events were categorized as mild by the investigator, 31.7% as moderate, and 4.9% as severe.
Discussion
This 12-week study of the efficacy, safety, and tolerability of sildenafil in the treatment of male patients with ED in Latin America was based on a double-blind, randomized, placebo-controlled, multicenter, flexible-dose escalation trial design. The administration of the study drug 'as required' in a flexible-dose escalation design closely replicates the conditions found in a community-based medical practice. 2 The study was performed in a natural environment, which meant that we had to rely on the men's own report of efficacy. However, the selfadministered questionnaire of the IIEF has a high degree of sensitivity and specificity for detecting treatment-related changes in men with ED. 16 This questionnaire, together with the GEAQ, provided a comprehensive assessment of erectile function, and the event log provided information about individual drug administrations.
Recognizing the fact that in most men ED is a multifactorial problem, we enrolled patients whose ED stemmed from a broad variety of causes. Overall, the results of the efficacy assessments demonstrated that sildenafil significantly improved erectile function and the success of intercourse. These efficacy results are consistent with other recently published sildenafil double-blind studies. 9 -14 The therapeutic response to sildenafil has been reported to be similar in men both with different etiologies and different degrees of severity of ED. 17 -24 Although the present Figure 5 Proportions of attempts at successful sexual intercourse (intent-to-treat analysis). Sildenafil citrate in the treatment of ED in Latin America E Becher et al study was not designed to address either of these questions in this population of men with ED from southern Latin America, a retrospective analysis of the present study (unpublished data) suggests that similar results can be expected across the different etiologies of ED. In addition, a specific analysis of the study efficacy data involving different degrees of organic ED shown in the present study (analysis of efficacy in patients presenting Rigiscan measurements above or below 50%, and above and below 70%), suggests that similar results can be expected across the different degrees of severity of organic ED. However, these conclusions must be confirmed by other prospective studies due to the small number of patients in the current one. In earlier studies, the mean scores on the IIEF after sildenafil therapy approached those of agematched men without ED. 4, 9 Although sildenafil did not affect the level of sexual desire in previous studies, the present trial found a significant increase in the mean score for sexual desire in patients taking sildenafil. This finding might be explained by the positive emotional influence exerted by the achieved improvement on penile erection capability, but we must acknowledge that it has no specific or definite explanation that can be attributed to the study drug. 6 -8 Sildenafil was well tolerated in our study. The main AEs were headache, flushing, and visual disturbances, and they were usually mild and transient. These AEs have been previously reported, with a similar degree of severity, in several sildenafil studies. 9 -14,17 -24 They reflect the pharmacologic nature of sildenafil as a PDE5 inhibitor, with modest vasodilator and weak PDE6 inhibitory properties. 6 -8 Few men discontinued sildenafil treatment, and the proportion of discontinuations was similar between the sildenafil and the placebo group, suggesting a relatively high level of drug tolerability and acceptance. None of the men enrolled in the sildenafil group experienced acute ischemic syndromes or sudden death as AEs. These results are in concordance with a recently presented report from Mittleman and colleagues that showed a similar incidence rate of death and myocardial infarction between the sildenafil and the placebo group in a pooled analysis of double-blind and open-label studies. 14 We believe this is the first study to demonstrate a positive correlation between the investigator's clinical assessment of Rigiscan determinations regarding ED etiology (organic vs psychogenic) in a clinical drug trial.
Conclusions
This 12-week study of the efficacy, safety, and tolerability of sildenafil in the treatment of male patients with ED in Latin America demonstrated that sildenafil significantly improved erectile function and the percent of successful intercourse attempts. These efficacy results are consistent with other recently published sildenafil double-blind and open-label studies.
Sildenafil was well tolerated. The most frequent AEs reported were headache and flushing, and they were usually mild and transient. The proportion of discontinuations was similar between the sildenafil and the placebo group, suggesting a relatively high level of drug tolerability and acceptance. None of the men enrolled in the sildenafil group experienced acute ischemic syndromes or sudden death as AEs.
A high degree of correlation was found regarding the etiologic diagnosis (ie, organic, psychogenic, or mixed) of ED in the investigator's clinical assessment and objective Rigiscan measurements. Sildenafil citrate in the treatment of ED in Latin America E Becher et al
